Systematic Analysis Of Expression Profiles Of SRSF Family Members For Prognostic Application In DLBCL

Abstract

Abstract Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin’s lymphoma. Serine and arginine-rich splicing factors (SRSF) family is an important splicing regulator and plays vital roles in RNA nuclear transportation and RNA stability. However, the role of the SRSF family in DLBCL is still unknown. The GEPIA database and the Human Protein Atlas were used to investigate the differential expression of SRSF in the DLBCL tissue and corresponding normal tissues. The mRNA expression profiles and clinicopathological data from the GSE10846 dataset from the Gene Expression Omnibus (GEO) database were downloaded to explore the clinical significance, prognostic value, and tumor immune microenvironments in DLBCL. SRSF family expression levels were substantially upregulated in DLBCL compared with normal tissues. Increased SRSF mRNA expression levels were associated with poorer overall survival. We selected 4 SRSF genes (SRSF1, SRSF7, SRSF10, and SRSF12) related to prognosis to conduct a risk model. Additionally, SRSF is strongly associated with MMR genes, DNA methyltransferase, and tumor stemness index. SRSF expression was closely correlated with infiltrating levels of specific types of immune cells in DLBCL, especially B cells naïve and T cell CD4 memory activated. Pathway enrichment analysis indicated that the SRSF family was involved in the upregulation of tumor metabolism and metastasis. Finally, SRSF protein was higher in DLBCL cell lines than in control cells by western blot. SRSF family genes have complicated roles in tumorigenesis, progression, and prognosis in DLBCL.